COVID-19 Antiviral Treatment

New treatment options for COVID-19 continue to emerge. Recently, two new oral antiviral treatment options have been granted Emergency Use Authorization (EUA) by the FDA. The EUA for PAXLOVID (nirmatrelvir/ritonavir) was issued on Dec. 22, 2021. The EUA for molnupiravir was issued on Dec. 23, 2021. These oral products are currently in very limited supply. To help guide the use of these medications, criteria for use (see links below) has been recommended by the Blue Chip COVID-19 Committee (an ad hoc committee of the NMMC Pharmacy and Therapeutics Committee) and approved by the NMMC Pharmacy and Therapeutics Committee. Locations where these treatment options are available, while supplies last, are listed below as well.

Paxlovid Criteria

Locations where NMHS currently has Paxlovid include:

Molnupiravir Criteria

Locations where NMHS currently has Molnupiravir include: